FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Schumacher Laura J
2. Issuer Name and Ticker or Trading Symbol

AbbVie Inc. [ ABBV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Vice Chairman
(Last)          (First)          (Middle)

1 N. WAUKEGAN ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

11/4/2019
(Street)

NORTH CHICAGO, IL 60064
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value  11/4/2019    G   V 358  D $0  164480  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Schumacher Laura J
1 N. WAUKEGAN ROAD
NORTH CHICAGO, IL 60064


Vice Chairman

Signatures
Steven L. Scrogham, attorney-in-fact for Laura J. Schumacher 11/8/2019
**Signature of Reporting Person Date


AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more AbbVie Charts.

News Abbvie Inc.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Donnerstag 25 April 2024 (9 Stunden vor) • PR Newswire (US)
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Dienstag 23 April 2024 (2 Tage vor) • PR Newswire (US)
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Donnerstag 18 April 2024 (1 Woche vor) • PR Newswire (US)
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Freitag 12 April 2024 (2 Wochen vor) • PR Newswire (US)
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
Dienstag 9 April 2024 (2 Wochen vor) • PR Newswire (US)
AbbVie to Host First-Quarter 2024 Earnings Conference Call
Donnerstag 4 April 2024 (3 Wochen vor) • PR Newswire (US)
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
Mittwoch 3 April 2024 (3 Wochen vor) • PR Newswire (US)
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Montag 1 April 2024 (3 Wochen vor) • GlobeNewswire Inc.
Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News
Dienstag 26 März 2024 (1 Monat vor) • IH Market News
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
Montag 25 März 2024 (1 Monat vor) • PR Newswire (US)
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Montag 25 März 2024 (1 Monat vor) • PR Newswire (US)
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Montag 25 März 2024 (1 Monat vor) • GlobeNewswire Inc.